CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Phase of Trial: Phase II
Latest Information Update: 22 May 2018
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 11 May 2018 Status changed from not yet recruiting to recruiting.
- 17 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.
- 07 Mar 2018 New trial record